Boston Scientific’s Renal Denervation Push: A Strategic Acquisition
In a significant move within the medtech sector, Boston Scientific has re-entered the renal denervation (RDN) race with a bold acquisition. On March 5th, 2025, the company announced the $540 million acquisition of SoniVie Ltd., an Israeli firm developing an ultrasound-based renal denervation system to treat uncontrolled hypertension. This acquisition signals Boston Scientific’s confidence in the future of the renal denervation devices market, a field that’s showing strong momentum following recent FDA approvals from Medtronic and Recor Medical. This blog is originally published here: https://www.lifesciencemarketr....esearch.com/insights
Mi piace
Commento
Condividi
